New combo therapy shows promise for tough childhood lymphoma

NCT ID NCT01920932

First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 16 times

Summary

This study tests whether adding a targeted drug (brentuximab vedotin) to standard chemotherapy and radiation can better treat children and teens with high-risk Hodgkin lymphoma. About 77 participants with stage IIB, IIIB, or IV disease will receive the new combination. The goal is to improve early cancer clearance and possibly reduce the need for radiation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE II CHILDHOOD HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana-Farber Harvard Cancer Center

    Boston, Massachusetts, 02115, United States

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California, 94304, United States

  • Maine Children's Cancer Program (MCCP)

    Scarborough, Maine, 04704, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • St. Jude Midwest Affiliate

    Peoria, Illinois, 61637, United States

Conditions

Explore the condition pages connected to this study.